Abstract
The use of data deriving from monitoring the time variation of the intensity of pharmacological effect(s) following dosing can often present an advantageous alternative to the more conventional approach of using chemical or radiological assay of blood and/or urine level data for bioavailability evaluations of drug products: bioavailability studies can be performed with drugs where no assay exists. A relatively simplified discussion of the general theoretical principles on which the use of pharmacological data is based and a stepwise description of the approach for its routine application in bioavailability studies are presented. Approaches for computing rates and extents of drug bioavailability vs. time profiles on analog and digital computers are qualitatively described and quantitatively presented in a subsequent report. The concept of preabsorption (gastrointestinal bioavailability) is introduced and biophasic availability of drugs to local sites of action is discussed.
Similar content being viewed by others
References
V. F. Smolen and W. A. Weigland. Drug bioavailability and pharmacokinetic analysis from pharmacological data.J. Pharmacokin. Biopharm. 1:329–336 (1973).
V. F. Smolen, P. B. Kuehn, and E. J. Williams. Idealized approach to the optimal design, development, and evaluation of drug delivery systems II: Drug bioavailability inputs andin-vitro drug release testing.Drug. Dev. Comm. 1:231–258 (1974/1975).
V. F. Smolen, R. D. Barile, and T. G. Theophanous. The relationship between dose, effect, time, and biophasic drug levels.J. Pharm. Sci. 61:467–470 (1972).
V. F. Smolen. Determination of time course ofin-vivo pharmacological effects fromin-vitro drug-release testing.J. Pharm. Sci. 60:878–882 (1971).
V. F. Smolen and W. A. Weigland. Optimally predictivein-vitro drug dissolution testing forin-vivo bioavailability.J. Pharm. Sci. (in press).
V. F. Smolen, E. J. Williams, and P. B. Kuehn. Bioavailability and pharmacokinetic analysis of chlorpromazine in humans and animals using pharmacological data.Can. J. Pharm. Sci. 10:95–106 (1975).
V. F. Smolen, H. R. Murdock, and E. J. Williams. Bioavailability analysis of chlorproma-zine from pupilometric data.J. Pharmacol. Exp. Ther. 195:404–415 (1975).
V. F. Smolen and R. D. Schoenwald. Drug absorption analysis from pharmacological data. I. The method and its confirmation exemplified for a mydriatic drug, tropicamide.J. Pharm. Sci. 60:96–103 (1971).
V. F. Smolen. Quantitative determination of drug bioavailability and biokinetic behavior from pharmacological data for ophthalmic and oral administration of a mydriatic drug.J. Pharm. Sci. 60:354–365 (1971).
V. F. Smolen. Optimal control of drug input and response dynamics: A role for biomedical engineering in pharmaceutical science.Am. J. Pharm. Ed. 37:107–125 (1973).
R. D. Schoenwald and V. F. Smolen. Drug absorption analysis from pharmacological data. II. Transcorneal biophasic availability of tropicamide.J. Pharm. Sci. 60:1039–1045 (1971).
V. F. Smolen, V. D. Turrie, and W. A. Weigand. Drug input optimization: Time optimal control of simultaneously occurring multiple pharmacological effects.J. Pharm. Sci. 61:1941–1952 (1972).
V. F. Smolen, P. B. Kuehn, and E. J. Williams. Idealized approach to the optimal design, development, and evaluation of drug delivery systems. I. Drug bioavailability input-pharmacological response output relationships.Drug Dev. Comm. 1:143–172 (1975).
V. F. Smolen. The determination of drug bioavailability characteristics from pharmacological data.Can. J. Pharm. Sci. 1:1–6 (1972).
A. K. Jhawar, Ph.D. dissertation, Department of Chemical Engineering, Purdue University, August 1974.
P. B. Kuehn. Ph.D. dissertation, Industrial and Physical Pharmacy Department, Purdue University, August 1974.
A. K. Jhawar, P. B. Kuehn, V. F. Smolen, and W. A. Weigand. Mathematical methods for evaluation of drug delivery systems. I. A frequency response method for pharmacokinetic model identification.J. Pharmacokin. Biopharm. (in review).
A. K. Jhawar, P. B. Kuehn, V. F. Smolen, and W. A. Weigand. Mathematical methods for evaluation of drug delivery systems. II. A generalized numerical deconvolution procedure for computing the amount of drug absorbed.J. Pharmacokin. Biopharm. (in review).
S. J. Pizer, A. B. Ashare, A. B. Callahan, and G. L. Brownel. Fourier transform analysis of tracer data. In F. Heinmets (ed.),Concepts and Models of Biomathematics: Simulation Techniques and Methods, Dekker, New York, 1969, pp. 105–129.
J. G. Wagner and E. Nelson. Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug.J. Pharm. Sci. 53:1392–1403 (1961).
J. C. K. Loo and S. Riegelman. New method for calculating the intrinsic absorption rate of drugs.J. Pharm. Sci. 57:918–928 (1969).
M. Hanano. Studies of absorption and excretion of drugs. VII. A new estimation method for the release of drugs from dosage forms and the availabilityin-vivo.Chem. Pharm. Bull. 15:994–1001 (1967).
L. Z. Benet. The use and application of deconvolution methods in pharmacokinetics. Abstracts of papers presented at the 13th National Meeting of the APhA Academy of Pharmaceutical Sciences, Chicago, November 5–9, 1972, pp. 169–171.
C. D. McGillem and G. R. Cooper.Continuous and Discrete Signal and System Analysis, prelim, ed., Chap. 4. Purdue University Press, Lafayette, Ind., 1973, Chap. 4.
M. Silverman and A. S. V. Burgen. Application of analog computer to measurement of intestinal absorption rates with tracers.J. Appl. Physiol. 16:911–913 (1961).
J. O. Osburn. Inverse simulation.Inst. Control Syst. 40:131–133 (1967).
J. S. Mattson, H. B. Mark, and H. C. MacDonald.Computer Fundamentals for Chemists, Dekker, New York, 1973, pp. 255–275.
V. F. Smolen. A study of drug bioavailability as related to physiological response. Quarterly Report of Research Progress No. 4 Food and Drug Administration Contract No. 73-23, May 30, 1974.
V. F. Smolen, Theoretical and computational basis for drug bioavailability determinations using pharmacological data. II. Drug input⇄response relationships.J. Pharmacokin. Biopharm. 4:355–375 (1976).
Author information
Authors and Affiliations
Additional information
Research supported by Food and Drug Administration Contract No. 223-73-3026, Alcon Laboratories, Fort Worth, Texas, and the Purdue Biomedical Engineering Center.
Rights and permissions
About this article
Cite this article
Smolen, V.F. Theoretical and computational basis for drug bioavailability determinations using pharmacological data. I. General considerations and procedures. Journal of Pharmacokinetics and Biopharmaceutics 4, 337–353 (1976). https://doi.org/10.1007/BF01063123
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01063123